| Value | ₹15.00 Cr |
|---|
BSE filing, NSE: SAIPARENT. Summary written from the filing by ALFA Finder's alert engine.
Sai Parenterals Ltd: key numbers
- Share price
- ₹484.05
- Market cap
- ₹2,138 Cr
- Revenue (annual)
- ₹381.0 Cr
- Net profit (annual)
- ₹14.26 Cr
- P/E (TTM)
- 103.0×Sector 46.1×
- Promoter holding
- 51.16%+0.00% QoQ
- FII holding
- 2.85%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Parenterals Ltd
All →Sai Parenterals Board Meeting Date
Sai Parenterals Ltd notified a Board Meeting on 1 Nov 2026 to approve unaudited Q2/H1 FY27 results. No financial figures or decisions are reported yet.
Sai Parenterals Acquisition Worth ₹15 Cr
Sai Parenterals Limited has acquired a 60% stake in Prathyak Laboratories Private Limited for ₹15 Crore. This acquisition provides an operational R&D facility in Hyderabad.
- Value
- ₹15.00 Cr
- product pipeline
- 150.0 SKUs
Sai Parenterals Other Announcement
Sai Parenterals Ltd submitted the Monitoring Agency Report for the quarter ended 30th June 2026 regarding the utilization of IPO proceeds, as per SEBI regulations.
Sai Parenterals Management Change
Sai Parenterals Limited appointed Mr. Ashwani Singh Bisht as Company Secretary and Mr. Arvind Gannimitta as COO. These appointments follow the resignation of Ms. Shivali Aggarwal.
Sai Parenterals Annual General Meeting
Sai Parenterals held its 25th Annual General Meeting on September 10, 2026. Shareholders approved financial statements, director appointments, and various company resolutions.
Sai Parenterals Bags ₹204 Cr Order
Sai Parenterals' subsidiary, Noumed Pharmaceuticals, renewed a 3-year OTC Medicines Supply Agreement with an Australian pharmacy chain, valued at approximately ₹204 Crore.
- Value
- ₹204.0 Cr
- Execution
- 3 years
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr